Biotech's Outlook Brightens, But Lab Landlords Face Deepening Vacancies, Falling Rents

Life sciences real estate remains under pressure, with nationwide vacancy rising to 23.2%, net negative absorption topping 1.1M SF, and asking rents falling for a fifth straight quarter to $67/SF. Of 60M SF of labs completed from 2020 to 2025, 55.6% are vacant, including 73.4% of 2025-vintage labs, though some space is being repurposed to AI, advanced manufacturing and defense-tech uses. Biotech fundamentals are improving, with $7.5B of VC raised in Q1 2026 and notable IPOs totaling more than $1.3B, but the benefits have not yet translated into a real estate recovery.

Analysis

The key setup is not “biotech recovery” but a lagging real-estate repricing to a demand regime that is improving only at the margin. That creates a second-order winner/loser split: diversified brokerage and leasing intermediaries with broad occupier exposure should stabilize sooner, while concentrated lab landlords remain trapped between high carrying costs and a tenant base that is still size-constrained and lease-term cautious. For owners with meaningful exposure to recently delivered product, every incremental lease signed likely comes at lower rent and higher TI/free-rent concessions than underwriting assumed, so NOI recovery will lag headline absorption by quarters, not months.

The more interesting catalyst is capital formation, not occupancy. If IPO windows stay open and VC stays above trend, the space need translates first into headcount growth and then into real estate demand; however, tenants are still optimizing for optionality, which means the first wave of demand mostly renews or takes small blocks rather than clearing large vacancies. That favors operators with flexible suites, plug-and-play offerings, and conversion optionality, while punishing landlords that relied on large, single-tenant lab deliveries. The conversion trend is itself a bearish signal for pure-play lab rent power, because alternative uses are effectively becoming the marginal buyer of distressed inventory.

The contrarian view is that the market may be underestimating how long it takes for funding to convert into square footage. Biotech equities can rerate quickly on financing optimism, but real estate demand has a much longer operating cycle, and the current vacancy overhang implies a multi-year digestion period even if leasing improves from here. So the near-term upside is in brokers and service providers tied to transaction velocity, not in landlords that need a full-cycle recovery to regain pricing power.

For Alexandria specifically, the risk is that asset quality bifurcation intensifies: trophy, core-campus assets can hold, but non-core or oversupplied markets may require more capital recycling, which pressures FFO growth and keeps multiple expansion capped. The upside case is a broader IPO/VC reopening that restores larger footprints in 2027+, but that is a longer-dated option, not a base case for the next few quarters.

Key Decisions for Investors

• Long CBRE vs short ARE for 3-6 months: benefit from rising leasing/brokerage activity and conversion/transaction volume while avoiding direct exposure to lab rent compression and vacancy overhang.
• For ARE holders, sell covered calls 1-2 quarters out against core positions to monetize low-volatility, range-bound upside; use rallies driven by biotech sentiment as de-risking windows.
• Initiate a small tactical long in CBRE on any post-earnings pullback: the stock should trade better as leasing velocity and restructuring/conversion assignments offset softer landlord fundamentals.
• Avoid adding to pure-play life sciences REIT exposure until vacancy trends improve for at least two consecutive quarters; the setup still implies negative operating leverage and continued rent pressure.
• If seeking optionality on a genuine biotech financing turn, prefer a basket of liquid tools on XBI rather than landlords: a 6-12 month call spread can express the thesis without underwriting a slow real-estate reset.